Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study
Dabbous et al., Archives of Virology, doi:10.1007/s00705-021-04956-9
Dabbous et al., Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study, Archives of Virology, doi:10.1007/s00705-021-04956-9
Jan 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
This study was retracted.
Dabbous et al., 25 Jan 2021, peer-reviewed, 10 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Archives of Virology (2021) 166:949–954 https://doi.org/10.1007/s00705-021-04956-9 BRIEF REPORT Efficacy of favipiravir in COVID‑19 treatment: a multi‑center randomized study C Received: 14 October 2020 / Accepted: 25 November 2020 / Published online: 25 January 2021 © The Author(s), under exclusive licence to Springer-Verlag GmbH, AT part of Springer Nature 2021 LE Hany M. Dabbous1 · Sherief Abd‑Elsalam2 · Manal H. El‑Sayed3 · Ahmed F. Sherief1 · Fatma F. S. Ebeid3 · Mohamed Samir Abd El Ghafar4 · Shaimaa Soliman5 · Mohamed Elbahnasawy6 · Rehab Badawi2 · Mohamed Awad Tageldin7 A R TI Abstract No specific antiviral drugs have been approved for the treatment of COVID-19. This study aimed to evaluate the efficacy of favipiravir in treatment of COVID-19. This was a multicenter randomized controlled study including 96 patients with COVID- 19 who were randomly assigned into a chloroquine (CQ) group and a favipiravir group. None of the patients in the favipiravir group needed mechanical ventilation (p = 0.129). One patient (2.3%) in the favipiravir group and two patients (4.2%) in the CQ group died (p = 1.00). Favipiravir is a promising drug for COVID-19 that decreases the hospital stay and the need for mechanical ventilation. ClinicalTrials.gov Identifier NCT04351295. TE D
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit